Clinical Trials
35 trialsNivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
Genetic Studies of Chronic Active Epstein-Barr Disease
National Institutes of Health Clinical Center (CC)
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
ALLELE
Pierre Fabre Medicament
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
National Institutes of Health Clinical Center (CC)
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
University of California, San Francisco
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Chinese PLA General Hospital
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age
ModernaTX, Inc.
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Chinese PLA General Hospital
RACSMEI
Institut Pasteur du Cambodge
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
National Taiwan University Hospital
VSTs
Children's Hospital Medical Center, Cincinnati
Third Party Viral Specific T-cells (VSTs)
Children's Hospital Medical Center, Cincinnati
CILESTE
Baylor College of Medicine
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
Thomas Jefferson University
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Stanford University
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
New York Medical College
TETRAVI
Baylor College of Medicine
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Columbia University
TRACE
University Hospital Freiburg
START-001
Marengo Therapeutics, Inc.
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
Sun Yat-sen University
Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection
University Hospital, Basel, Switzerland
MECFS-R
Technical University of Munich
R-MVST Cells for Treatment of Viral Infections
Columbia University
EBVAST
Labo'Life
Deep Learning-based sbORN Diagnostic Model
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
REPLY
University Hospital, Strasbourg, France
Evaluation of CMV/EBV-CMI in Haploid HSCT
The First Affiliated Hospital of Soochow University
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
Sun Yat-sen University
Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
Hunan Cancer Hospital
GI-hNeoT-01
BGI, China
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
Chinese PLA General Hospital
MUC-CFS
Technical University of Munich
Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
Huazhong University of Science and Technology